Albumin News and Research

RSS

Genetically engineered blood protein can be used to split water into oxygen and hydrogen

Scientists have combined two molecules that occur naturally in blood to engineer a molecular complex that uses solar energy to split water into hydrogen and oxygen, says research published in the Journal of the American Chemical Society.

2 Dec 2006

Study shows Diovan reduced urinary protein excretion in patients with type 2 diabetes and high blood pressure

In patients with high blood pressure and type 2 diabetes, the blood pressure-lowering medication Diovan (valsartan) significantly reduced urinary protein excretion, with high doses providing the greatest sustained reduction , according to data presented at the Amer ican Heart Association's (AHA) Annual Scientific Sessions.

13 Nov 2006

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.

5 Oct 2006

Key parameters for encapsulating drugs in nanoparticles

One of the early, successful uses of nanoparticles has been to develop delivery vehicles capable of ferrying large amounts of water-insoluble drugs to tumors.

2 Oct 2006

New developments in the technique of partial nephrectomy

While partial nephrectomy has demonstrated oncologic equipoise with radical nephrectomy, it remains a surgically daunting procedure that can be associated with significant complications, particularly related to hemostasis and prevention of post-operative urinary fistulae.

1 Sep 2006

Birch bark compound may be potent prostate cancer fighter

A compound found in the bark of the white birch tree - betulonic acid, a derivative of betulinol - may finally have been rendered a water-soluble, bio-available drug, and is already showing the potential to be a possible agent against prostate cancer - in cell culture and in an animal model.

25 Jul 2006

Herceptin-linked nanoparticles for targeted cancer therapy

Albumin nanoparticles have recently proven their mettle as anticancer agents with the 2005 approval of Abraxane to treat metastatic breast cancer.

17 Jul 2006

Yttrium-90 to control hepatocarcinoma

The University Hospital at the University of Navarra is the only centre throughout the entire Spanish state for the treatment of liver tumours by means of radioembolisation and the one with the greatest accumulated experiences in the treatment throughout Europe.

10 Jul 2006

Advancing nanoparticle-based imaging and therapy of brain cancer

Brain cancer is one of the most difficult malignancies to detect and treat, in large part because of the difficulty in getting imaging and therapeutic agents past the so-called blood-brain barrier and into the brain.

9 May 2006

Plain language labels now required for eight top allergens

If you or someone in your family suffers from a food allergy, you know how difficult it can be to decipher the food label if the product contains an offending substance.

20 Apr 2006

Study shows mercury amalgam fillings pose no health concerns for children

There were no statistically significant differences in neuropsychological and neurobehavioral effects among children whose dental caries were treated with mercury amalgam fillings and those treated with a composite dental restorative material

18 Apr 2006

Minimal nutritional requirements for growing and maintaining human embryonic stem cells

Researchers at Yale have established the minimal nutritional requirements for growing and maintaining human embryonic stem cells, a recipe that is critical for clinical application and for developmental studies, according to a report in the Proceedings of the National Academy of Sciences.

11 Apr 2006

Newly discovered testosterone effect may act on prostate cancer

A newly-discovered mode of action of testosterone is showing great promise in the fight against prostate cancer, with tests showing a 60% reduction in tumor size in mice.

6 Apr 2006

Tobacco plants being used to produce human albumin

Human serum albumin (HSA) is the intravenous protein most commonly used in the world for therapeutic ends. It is employed to stabilise blood volume and to avoid risk of a heart attack, its administration in operating theatres being almost a daily occurrence.

27 Mar 2006

Simple method to diagnose preeclampsia

Researchers at Yale School of Medicine have found that analyzing proteins in urine is a simple and objective method to diagnose and classify preeclampsia (PE), a complication of pregnancy causing high blood pressure after 20 weeks of gestation.

5 Feb 2006

Kidney disease may be a more important risk factor for heart disease than is cholesterol

Jefferson researchers have found that mice with low levels of the protein hormone adiponectin may also have high levels of a protein called albumin which, in humans, may be a sign of kidney disease.

28 Nov 2005

Research points way to more effective delivery of medicine around the body

New research showing how drugs stick to a key protein in the bloodstream could help to create drugs that are delivered more effectively to organs in the body.

13 Oct 2005

New role for the blood protein serum amyloid P in the body's response to medical materials

Using a technique called proteomics, the researchers identified many of the blood proteins that stick (adsorb) to the surfaces of medical devices. Blood proteins that adsorb to the surfaces of materials unfold and can be recognized by the body, which then mounts a response against the device.

5 Oct 2005

Call for closer examination of a metabolic syndrome

Two major health organizations in Europe and the United States are calling for closer examination of a syndrome that has been widely believed to predict the risk of developing heart disease, questioning whether it has been appropriately defined and whether it is in fact a syndrome at all.

25 Aug 2005

Ruboxistaurin shows favorable effects on kidney damage and function in people with type 2 diabetes and nephropathy

Eli Lilly and Company today announced encouraging results from a one-year pilot study examining the effect of ruboxistaurin mesylate in persons with type 2 diabetes and kidney disease (also known as "diabetic nephropathy").

12 Jun 2005